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Introduction
The Oman Respiratory Society, in collaboration with College of Medicine & Health Sciences, Sultan Qaboos University, held its 
2nd National Chronic Obstructive Pulmonary Disease (COPD) Symposium on 14th October 2010, which was celebrated as World 
Spirometry Day by the European Respiratory Society and the European Lung Foundation. The Oman Respiratory Society supported 
this event by conducting a workshop on spirometry in the afternoon.  Primary care physicians and the other health care workers got 
hands-on experience in performing and interpreting spirometry. A workshop on non-invasive ventilation was also organised on the 
same day. The symposium was held under the auspices of His Excellency Dr. Abdullah Al-Futaisi, Executive President of the Oman 
Medical Specialty Board. 
selected abstracts
COPD: Definition and pathophysiology
Issa Al-Jahdhami
Department of Medicine, Armed Forces Hospital, Muscat, Oman. Email: essajah111@yahoo.co.uk.
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterised by irreversible airway obstruction. 
It is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases. Though 
common, COPD often remains under diagnosed. The exact prevalence worldwide is unknown, but varies from 7–19% in different 
studies. The prevalence increases with age and is variable between different countries. In the United States more than 12.7 million patients 
were diagnosed with COPD in 2005. The exact incidence in Oman is unknown. In women, COPD is most commonly misdiagnosed 
as asthma. Smoking is the main risk factor for COPD. In healthy non-smokers, lung function normally declines by around 20 ml per 
year. This decline is accelerated in smokers. Other risk factors include exposure to smoke from biomass fuels used for cooking in rural 
areas, organic dust in crops and animal farming and also to chemicals in the plastics and textile industries. Outdoor air pollution, long 
standing asthma and bronchiectasis can also lead to irreversible airway obstruction. Exposure to smoke and various noxious agents 
starts a cascade of inflammatory processes that lead to small airway remodelling and loss of alveolar attachments with decrease of elastic 
recoil. This inflammation is mainly driven by neutrophils with the release of various cytokines. COPD leads to disabling symptoms and 
substantial mortality. 
Functional Assessment in COPD
Omar Al-Rawas
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. Email: orawas@squ.edu.om.
Functional assessment, a major component of COPD management, helps in the differential diagnosis, the classification of COPD 
and in treatment decisions. Assessment consists of several components and steps including history taking, clinical examination and 
investigations. The focus of this presentation is on the objective physiological investigations such as spirometry, extended lung function 
testing, cardiopulmonary exercise testing, and respiratory muscle strength estimation. Spirometry is the main investigation and should 
be done in all patients suspected of having COPD. This has to be made available at all the levels of health care facility providing care 
for COPD patients.  In the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, spirometric values are used for 
the definition and classification of COPD severity. The presence of airway obstruction is confirmed by a post bronchodilator forced 
expiratory volume 1 (FEV1)/forced vital capacity (FVC) value of less than 70% and is then further classified based on FEV1 values (Stage 
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I: Mild - FEV1 ≥80%; Stage II: Moderate - FEV1 -50 to <80%; Stage III: Severe - FEV1 -30 to <50%, and Stage IV: Very Severe - FEV1 
<30% predicted). Spirometry before and after bronchodilator administration identifies reversibility of airway obstruction and helps 
to distinguish COPD from asthma. Lung volume measurements identify air trapping and hyperinflation which are characteristics of 
emphysema. This is considered when there is an uncertainty about the diagnosis and should be available in all secondary care hospitals. 
The pulmonary diffusing capacity (lung transfer factor), a non-invasive index of gas exchange, is reduced in emphysema, but remains 
normal in pure chronic bronchitis and asthma. Cardiopulmonary exercise testing helps in the differential diagnosis of patients with 
exertional dyspnoea and objectively quantifies the severity of exercise limitation. The other useful functional tests include arterial blood 
gases, respiratory muscle strength testing and the six-minute walk test.
Management of Chronic Stable COPD
Jayakrishnan B
Department of Medicine, Sultan Qaboos University Hospital , Muscat, Oman. Email: drjayakrish@hotmail.com.
The goals of treatment in COPD are to relieve, improve and reduce symptoms and also to reduce the frequency and severity of 
exacerbations. A stepwise, comprehensive approach combining pharmacotherapy and non-pharmacotherapeutic interventions 
is needed to achieve this. Annual influenza vaccination reduces the mortality, morbidity and also the frequency of hospitalisations. 
Periodic pneumococcal vaccination is recommended in patients over 65 years, or in patients with a forced expiratory volume 1 (FEV1) 
of <40%. Education about the chronic nature of the disease, the purpose and dosing of medications and the inhaler technique is 
needed. Bronchodilators form the mainstay of pharmacological therapy for COPD. They decrease airway smooth muscle tone, improve 
the expiratory flow rates and reduce hyperinflation. Short acting bronchodilators, both β2-agonists (salbutamol, terbutaline) and 
anticholinergics (ipratropium bromide) improve pulmonary function, dyspnoea and exercise performance. Long-acting β2-agonists 
(LABA) produce sustained improvements in pulmonary function and dyspnoea, but the effects of LABA on exercise performance have 
been inconsistent. Long acting anticholinergics (LAAC) provide sustained improvement and also improves exercise endurance. There 
is evidence that the combination of LAAC (tiotropium bromide) and LABA (salmeterol, formoterol) produce additive improvement in 
pulmonary function. Patients with mild COPD should be provided with a short acting bronchodilator, to be taken on an ‘as and when 
needed’ basis. Short-acting β2-agonists and anticholinergics can be used alone or in combination. If the disease severity increases 
from mild to moderate, it is quite logical to add a long acting bronchodilator, either LABA or LAAC. Theophylline clearly has a 
bronchodilatory effect, but given the risk of side effects it should not be considered as a first line drug. In patients with stage II-IV COPD 
whose symptoms are not well controlled with a single long-acting bronchodilator, the combination of both an anticholinergic and a β2-
agonist long-acting bronchodilator may provide better symptom relief. For repeated exacerbations, or for patients with stage III disease, 
long-term inhaled corticosteroids (ICS) are indicated. Inhaled steroids decrease exacerbations and modestly slow the progression of 
respiratory symptoms, but have little impact on lung function and mortality. Regular treatment with ICS is advised for symptomatic 
COPD patients with an FEV1 <50% predicted and repeated exacerbations. In patients with severe disease triple therapy with LABA, 
ICS and LAAC are often preferred. Thick tenacious secretions could cause a major problem, but there is no evidence that thinning 
or increasing the clearance of secretions can bring about clinical improvement. Supplemental therapies, such as oxygen, pulmonary 
rehabilitation, and smoking cessation also play an important role in treatment. In patients not responding to treatment, comorbid 
conditions like continued smoking, coronary heart disease, heart failure, pulmonary hypertension and thromboembolic disease should 
be considered. New therapeutic options include phosphodiesterase-4 inhibitors (Roflumilast) and Indacaterol, a novel once daily ultra 
long-acting β2-agonist.
Management of Acute Exacerbation of COPD
Nabil M Al-Lawati
Department of Medicine, Royal Hospital, Muscat, Oman. Email: nabil.allawati@gmail.com.
An acute exacerbation of COPD (AECOPD) is defined as an acute change in patient’s dyspnoea, cough and/or sputum volume or 
purulence. AECOPD is the most frequent cause of medical visits, hospital admissions and death among patients with COPD. These 
events are an important determinant of quality of life and each attack further accelerates lung function decline. Short-term mortality 
from AECOPD in patients with mild to moderate COPD can be as high as 24% for those needing intensive care. Infections, both viral 
and bacterial, account for 60% of the precipitating factors. Risk factors include advanced age, chronic mucous hypersecretion, admission 
with an exacerbation in the previous year and the presence of comorbidities such as diabetes or heart failure. General indicators for 
hospital admission include acute respiratory acidosis, worsening hypoxemia, marked dyspnoea, altered sensorium and inability to care 
for oneself. The immediate measure is to give controlled oxygen therapy to alleviate hypoxaemia and improve tissue oxygenation. 
Venturi masks are the preferred interface for such therapy. Short acting bronchodilators namely salbutamol and ipratropium bromide 
given via a nebuliser work synergistically to improve airflow. Systemic corticosteroids are indicated for moderate to severe attacks and 
in particular if the forced expiratory volume 1 (FEV1) is less than 50% predicted. Corticosteroids have been shown to shorten recovery 
time, improve lung function in terms of FEV1 and arterial oxygenation and reduce the risk of early relapse. Unlike asthma, antibiotics 
have a major role in management of moderate to severe AECOPD. They can reduce the short term mortality by 77%. Aminophylline is 
not recommended routinely in the acute setting as they lack efficacy and can contribute to the development of serious side effects. One 
of the major recent advances in management of an acute exacerbation is the use of non-invasive positive pressure ventilation (NIV). This 
should be started for every patient with a respiratory rate of more than 25, arterial pH of < 7.35 and a PaCO2 of >45mmHg without any 
delay. NIV reduces the work of breathing by 60%; moreover, it obviates the need for mechanical ventilation, decreases treatment failure 
and short-term mortality by as much as 50%. Finally mechanical ventilation may be needed in very sick and unstable patients, or in those 
who either fail or are thought to be unsuitable candidates for NIV.
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Systemic Effects and Mortality in COPD
Yacoub Al-Mahrooqui
Department of Medicine, Royal Hospital, Muscat, Oman. Email: yaqpal@yahoo.com.
COPD is a systemic disease. In addition to causing pulmonary abnormalities, COPD is associated with systemic consequences outside 
the lungs. The comorbidities associated with this disease include skeletal muscle dysfunction, cardiovascular disease, osteoporosis, 
anaemia, metabolic abnormalities, depression and gastrointestinal diseases. Higher rates of hospitalisation are common among COPD 
patients who have comorbidities. Because these consequences can seriously affect quality of life and worsen prognosis, preventing 
and treating the systemic effects is important in COPD management. Persistent local and systemic inflammation and oxidative stress 
may contribute to these changes. Several studies had shown the elevation of various inflammatory markers in COPD like C reactive 
protein, tumor necrosis factor alpha, fibrinogen, leucocytes and vascular endothelial growth factor. Fat free mass is often low in COPD. 
Risk of developing ischaemic heart disease or stroke is higher among COPD patients. They are also at risk of developing osteoporosis. 
The prevalence of diabetes and metabolic syndromes is also higher among COPD patients. Respiratory failure is the leading cause of 
mortality followed by cardiovascular disease and lung cancer. Validated indices are often used to classify the severity of disease and 
predict the outcome or mortality. When, forced expiratory volume 1 (FEV1), the widely used prognostic indicator, is low it is associated 
with an increased risk of all-cause mortality. In summary, in COPD one should look for comorbidities, and in smokers with the above 
problems look for COPD as well.
Non-Pharmacological Management of COPD
Dimitrije Ponomarev
Department of Medicine, Royal Hospital, Muscat, Oman. Email: dponomarevster@gmail.com.
The components of non-pharmacological management of COPD are: 1) Rehabilitation; 2) Oxygen therapy; 3) Ventilatory support, 
and 4) Surgical management. The goals of rehabilitation include the reduction of symptoms, improvement of quality of life, increasing 
physical and emotional participation in everyday activities and reducing health care costs by stabilising or reversing the systemic 
manifestations of the disease. Non-pulmonary problems that cannot be treated by medicines are de-conditioning, relative social 
isolation, depression, muscle wasting, and weight loss. Rehabilitation programs can contribute to the improvement of exercise capacity, 
reduction of the perceived intensity of breathlessness, reduction of anxiety and depression, improvement of health-related quality of 
life, and reduction in the number of hospital admissions and length of hospital stay. Comprehensive pulmonary rehabilitation should 
involve a team of various medical specialists involved in exercise training, nutrition counselling, education and psychological support. 
The primary goal of oxygen therapy is to increase the baseline oxygen level to at least 8 kPa (60 mmHg) or to produce a SpO2 of at 
least 90% in the waking state. In the long term this brings a beneficial effect to haemodynamics, haematological characteristics, exercise 
capacity, lung mechanics and mental state. The benefits of non-invasive ventilatory support include the improvement of inspiratory flow 
rate, correction of hypoventilation, rest to respiratory muscles and resetting central respiratory drive. Non-invasive nocturnal positive 
pressure ventilation is indicated in hypercapnic patients with COPD who have recurrent oxygen desaturation during sleep despite the 
use of supplemental oxygen; moreover, it is useful in patients recovering from an acute exacerbation that required the use of mechanical 
ventilation. Surgical management of COPD includes bullectomy and lung volume reduction surgery. Bullectomy is indicated if the bulla 
occupies ≥50% of the hemithorax and produces definite displacement of the adjacent lung. Lung volume reduction is a recent surgical 
technique where parts of the lung are removed to reduce hyperinflation which in turn improves the mechanical efficiency of respiratory 
muscles leading to an improvement in the overall gas exchange. Lung transplantation can be considered in selected patients when forced 
expiratory volume 1 (FEV1) is less than 25% of the predicted value with features of respiratory failure
Smoking Cessation
Zahir A. M. Al-Anqoudi
Control of Non-Communicable Diseases Section, Directorate General of Health Services - Dakhilyah Region, Nizwa, Oman. Email: alanqoudi@gmail.com.
Statistics indicate that it will not be possible to reduce tobacco-related deaths over the next 50 years, unless adult smokers are 
encouraged to quit. The World Health Organization (WHO) emphasises the need to have a multiple approach strategy including 
taxation, legislation, a ban on pro-tobacco advocacy and encouraging tobacco cessation  rogrammes. The addiction starts with nicotine 
use for pleasure, enhanced performance and mood regulation and slowly tolerance and physical dependence develop. The process of 
addiction has three main aspects: physiological, due to nicotine; behavioural, where it is linked to different day-to-day behaviours and 
psychological, which is seen mostly in patients with depression or anxiety. Unfortunately, although a good percentage of smokers are 
considering cessation, the medical team somehow fails to reach them. Physicians, especially the primary care providers, have a role in all 
aspects of care. The “5A” intervention approach serves as a guide: Ask about tobacco use on every visit—this could easily be practised by 
including this questions in the vital signs chart; Advice patients to quit; Assess willingness to make a quit attempt; Assist by helping the 
patient formulate a quit plan, and Arrange follow-up contact to prevent relapses. The main step at the level of primary care team is the 
(Ask) screening. The management of tobacco cessation is a behavioural approach for those with a low Fagerström addiction score and 
the use of pharmacological therapy in selected cases. The “5R’s” in the behavioural approach are: Relevance, motivational information 
being more effective if it is relevant to a patient's circumstances; Risks, emphasising the acute and long-term risks of smoking; Rewards, 
identifying potential benefits of smoking cessation; Roadblocks, detection of the barriers, and Repetition, repeating the motivational 
interventions at each visit. Drug therapy doubles the chance of long term cessation. This includes several forms of nicotine replacement 
therapy and Bupropion. The selective serotonin re-uptake inhibitors, Nortriptyline and Naltrexone, are not that effective. The Nizwa 
Healthy Lifestyle Project, a community based initiative with technical support from the Ministry of Health and the WHO, is running 
a tobacco cessation clinic staffed by family physicians, nurses, dietitians and dentists. Behavioural and motivational approaches, drug 
therapy and follow-up telephone calls are the tools employed. The preliminary data on a 5-month abstinence is encouraging, reaching 
an impressive 62%. We recommend extending our local experience so that tobacco cessation clinics are established throughout Oman 
with an initial focus on regions of high prevalence.
